{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:43:30Z","timestamp":1776941010987,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Environ Biophys"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00411-025-01137-z","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:52:32Z","timestamp":1753854752000},"page":"423-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Human dose estimation of a novel SPECT imaging agent using animal experimental data and Monte Carlo simulation"],"prefix":"10.1007","volume":"64","author":[{"given":"Samaneh","family":"Zolghadri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fateme","family":"Taati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arezou","family":"Karimian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7112-3847","authenticated-orcid":false,"given":"Hassan","family":"Yousefnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohannes","family":"Sardjono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"1137_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1515\/ract-2024-0298","volume":"112","author":"L Akbari","year":"2024","unstructured":"Akbari L, Sina S, Zolghadri S, Moghaddasi A, Hadad K, Yousefnia H (2024) [113mIn] In-PSMA: high potential agent for SPECT imaging of prostate cancer. Radiochim Acta 112:883\u2013894. https:\/\/doi.org\/10.1515\/ract-2024-0298","journal-title":"Radiochim Acta"},{"issue":"3","key":"1137_CR2","first-page":"5","volume":"32","author":"IC Ann","year":"2002","unstructured":"Ann IC (2002) Basic anatomical and physiological data for use in radiological protection: reference values. Ann ICRP 32(3):5","journal-title":"Ann ICRP"},{"key":"1137_CR4","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s002590100597","volume":"28","author":"OC Boerman","year":"2001","unstructured":"Boerman OC, Oyen WJ, Corstens FH (2001) Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med 28:1447\u20131449. https:\/\/doi.org\/10.1007\/s002590100597","journal-title":"Eur J Nucl Med"},{"key":"1137_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR (2009) MIRD pamphlet 21: A generalized schema for radiopharmaceutical dosimetry\u2014Standardization of nomenclature. J Nucl Med 50:477\u2013484. https:\/\/doi.org\/10.2967\/jnumed.108.056036","journal-title":"J Nucl Med"},{"key":"1137_CR6","first-page":"99","volume":"45","author":"F Bolorinovin","year":"2024","unstructured":"Bolorinovin F, Mirzaei M, Faghihi R, Joharidaha F, Sina S, Hadad K, Yousefnia H (2024a) Design and construction of a 113Sn\/113mIn generator using irradiation of natural indium in a cyclotron accelerator. J Nucl Sci Eng Technol 45:99\u2013106","journal-title":"J Nucl Sci Eng Technol"},{"key":"1137_CR7","first-page":"29","volume":"45","author":"F Bolorinovin","year":"2024","unstructured":"Bolorinovin F, Mirzaei M, Faghihi R, Joharidaha F, Sina S, Hadad K, Badipa F, Yousefnia H (2024b) Preparation, quality control, and biodistribution of [113mIn]In-DOTATATE. J Nucl Sci Technol 45:29\u201335","journal-title":"J Nucl Sci Technol"},{"key":"1137_CR8","doi-asserted-by":"publisher","first-page":"849407","DOI":"10.3389\/fmed.2022.849407","volume":"9","author":"J Bolotin","year":"2022","unstructured":"Bolotin J, Kagan L (2022) Emerging applications of SPECT radiopharmaceuticals in oncology. Front Med (Lausanne) 9:849407. https:\/\/doi.org\/10.3389\/fmed.2022.849407","journal-title":"Front Med (Lausanne)"},{"key":"1137_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2214\/ajr.109.4.735","volume":"109","author":"VA Brookeman","year":"1970","unstructured":"Brookeman VA, Sun PC, Bruno FP, Dunavant BG, Mauderli W (1970) Internal distribution and absorbed dose calculations for radioactive indium liver and lung scanning agents. Am J Roentgenol 109:735\u2013741. https:\/\/doi.org\/10.2214\/ajr.109.4.735","journal-title":"Am J Roentgenol"},{"key":"1137_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF00345866","volume":"2","author":"EH Burrows","year":"1971","unstructured":"Burrows EH (1971) Hirn-Szintigraphie Mit Radio-Indium. Eine kritische \u00fcbersicht. AJNR Am J Neuroradiol 2:15\u201323. https:\/\/doi.org\/10.1007\/BF00345866","journal-title":"AJNR Am J Neuroradiol"},{"key":"1137_CR11","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3390\/cancers15061631","volume":"15","author":"V Chernov","year":"2023","unstructured":"Chernov V, Rybina A, Zelchan R, Medvedeva A, Bragina O, Lushnikova N, Doroshenko A, Usynin E, Tashireva L, Vtorushin S, Abouzayed A (2023) Phase I trial of [99mTc] Tc-maSSS-PEG2-RM26, a Bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors. Cancers 15:1631. https:\/\/doi.org\/10.3390\/cancers15061631","journal-title":"Cancers"},{"key":"1137_CR13","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms23095023","volume":"23","author":"G Cri\u0219an","year":"2022","unstructured":"Cri\u0219an G, Moldovean-Cioroianu NS, Timaru DG, Andrie\u0219 G, C\u0103inap C, Chi\u0219 V (2022) Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade. Int J Mol Sci 23:5023. https:\/\/doi.org\/10.3390\/ijms23095023","journal-title":"Int J Mol Sci"},{"key":"1137_CR14","doi-asserted-by":"crossref","unstructured":"Cristy M, Eckerman KF (1987) Specific absorbed fractions of energy at various ages from internal photon sources. ORNL report ORNL\/TM-8381. Oak Ridge National Laboratory","DOI":"10.2172\/6233735"},{"key":"1137_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/cbr.2014.1741","volume":"30","author":"A Dash","year":"2015","unstructured":"Dash A, Chakraborty S, Pillai MR, Knapp FF Jr (2015) Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm 30:47\u201371. https:\/\/doi.org\/10.1089\/cbr.2014.1741","journal-title":"Cancer Biother Radiopharm"},{"key":"1137_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0001-2998(05)80173-4","volume":"20","author":"MK Dewanjee","year":"1990","unstructured":"Dewanjee MK (1990) The chemistry of 99mTc-labeled radiopharmaceuticals. Semin Nucl Med 20:5\u201327. https:\/\/doi.org\/10.1016\/S0001-2998(05)80173-4","journal-title":"Semin Nucl Med"},{"key":"1137_CR18","unstructured":"European Medicines Agency (2008) Guideline on Radiopharmaceuticals \/ eudralex 3AQ20a. EMA\u2013 CHMP"},{"key":"1137_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.remnie.2021.03.022","volume":"40","author":"TM Fuertes","year":"2021","unstructured":"Fuertes TM, Garc\u00eda FG, Montes MP, Grande MD, Fern\u00e1ndez NM, de Iturriaga Pi\u00f1a AG, Gabi\u00f1a PM (2021) Description of the methodology for dosimetric quantification in treatments with 177Lu-DOTATATE. Rev Esp Med Nucl Imagen Mol 40:167\u2013178. https:\/\/doi.org\/10.1016\/j.remnie.2021.03.022","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"1137_CR21","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1093\/eurheartj\/ehr057","volume":"32","author":"O Gaemperli","year":"2011","unstructured":"Gaemperli O, Bengel FM, Kaufmann PA (2011) Cardiac hybrid imaging. EHJ 32:2100\u20132108. https:\/\/doi.org\/10.1093\/eurheartj\/ehr057","journal-title":"EHJ"},{"issue":"1","key":"1137_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41181-023-00198-5","volume":"8","author":"V Gomez-Vallejo","year":"2023","unstructured":"Gomez-Vallejo V, Martin A, Baz Z, Llop J (2023) Advances in radiopharmaceutical development for targeted imaging and therapy: balancing efficacy and safety. EJNMMI Radiopharm Chem 8(1):6. https:\/\/doi.org\/10.1186\/s41181-023-00198-5","journal-title":"EJNMMI Radiopharm Chem"},{"key":"1137_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/radiation1010004","volume":"1","author":"M Haendeler","year":"2020","unstructured":"Haendeler M, Khawar A, Ahmadzadehfar H, K\u00fcrpig S, Meisenheimer M, Essler M, Gaertner FC, Bundschuh RA (2020) Biodistribution and radiation dosimetric analysis of [68Ga] Ga-RM2: a potent GRPR antagonist in prostate carcinoma patients. Radiat 1:33\u201344. https:\/\/doi.org\/10.3390\/radiation1010004","journal-title":"Radiat"},{"key":"1137_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14407\/jrpr.2023.00087","volume":"49","author":"EY Han","year":"2006","unstructured":"Han EY, Bolch WE, Eckerman KF (2006) Revisions to the ORNL series of adult and pediatric computational phantoms for use with the MIRD schema. HPHY 49:1\u201318. https:\/\/doi.org\/10.14407\/jrpr.2023.00087","journal-title":"HPHY"},{"key":"1137_CR26","unstructured":"Hermes Medical Solutions (2024) Internal radionuclide dose calculation. URL: https:\/\/www.hermesmedical.com\/our-software\/dosimetry\/olinda\/"},{"issue":"1","key":"1137_CR27","first-page":"49","volume":"2","author":"NR Hidayati","year":"2015","unstructured":"Hidayati NR, Hardiansyah D, Glatting G (2015) Effect of deviation in image quantification for internal dosimetry assessment in radionuclide therapy. Res Dev Nanotech Indon 2(1):49","journal-title":"Res Dev Nanotech Indon"},{"key":"1137_CR28","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","volume":"23","author":"JB Hjelmborg","year":"2014","unstructured":"Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, Pukkala E, Christensen K, Adami HO, Holm NV, Nuttall E (2014) The heritability of prostate cancer in the nordic twin study of Cancer. CEBP 23:2303\u20132310. https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-0568","journal-title":"CEBP"},{"issue":"10","key":"1137_CR32","doi-asserted-by":"publisher","first-page":"7779","DOI":"10.1007\/s00432-023-04724-z","volume":"149","author":"SM Hosseini","year":"2023","unstructured":"Hosseini SM, Mohammadnejad J, Yousefnia H (2023) Development of 177Lu-cetuximab-PAMAM dendrimeric nanosystem: a novel theranostic radioimmunoconjugate. J Cancer Res Clin Oncol 149(10):7779\u20137791","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"1137_CR29","first-page":"1","volume":"22","author":"ICRP","year":"1992","unstructured":"ICRP (1992) Radiological protection in biomedical research. ICRP publication 62. Ann ICRP 22(3):1\u2013189","journal-title":"Ann ICRP"},{"issue":"2\u20134","key":"1137_CR30","first-page":"1","volume":"37","author":"ICRP","year":"2007","unstructured":"ICRP (2007) The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP 37(2\u20134):1\u2013332","journal-title":"Ann ICRP"},{"key":"1137_CR31","unstructured":"Isotope Browser (2024) Available at: [https:\/\/play.google.com\/store\/apps\/details?id=iaea.nds.nuclides&hl=en&pli=1] (version: October 22)"},{"key":"1137_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.24200\/jon.2022.1018","volume":"2","author":"S Karimkhani","year":"2022","unstructured":"Karimkhani S, Yousefnia H, Faghihi R, Gramifar P, Parishan MR (2022) Calculation of Gallium-68 dose factors for [68Ga] DOTATATE injected patients: a comparison with OLINDA database. J Nucl Res Appl 2:30\u201340. https:\/\/doi.org\/10.24200\/jon.2022.1018","journal-title":"J Nucl Res Appl"},{"key":"1137_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","volume":"47","author":"J Kurth","year":"2020","unstructured":"Kurth J, Krause BJ, Schwarzenb\u00f6ck SM, Bergner C, Hakenberg OW, Heuschkel M (2020) First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: A radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. EJNMMI 47:123\u2013135. https:\/\/doi.org\/10.1007\/s00259-019-04504-3","journal-title":"EJNMMI"},{"key":"1137_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14407\/jrpr.2023.00087","volume":"49","author":"C Lee","year":"2024","unstructured":"Lee C (2024) A review of organ dose calculation methods and tools for patients undergoing diagnostic nuclear medicine procedures. J Radiat Prot Res 49:1\u201318. https:\/\/doi.org\/10.14407\/jrpr.2023.00087","journal-title":"J Radiat Prot Res"},{"key":"1137_CR37","unstructured":"Leung K (1999) 111In-DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 111In-RM2. Eur PMC"},{"key":"1137_CR38","volume-title":"MIRD primer for absorbed dose calculations","author":"R Loevinger","year":"1988","unstructured":"Loevinger R, Budinger TF, Watson EE (1988) MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York"},{"key":"1137_CR39","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s41365-023-01315-y","volume":"34","author":"XY Luo","year":"2023","unstructured":"Luo XY, Qiu R, Wu Z, Yan SC, Hu ZY, Zhang H, Li JL (2023) THUDose PD: a three-dimensional Monte Carlo platform for Phantom dose assessment. Nucl Sci Tech 34:164. https:\/\/doi.org\/10.1007\/s41365-023-01315-y","journal-title":"Nucl Sci Tech"},{"issue":"6","key":"1137_CR41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/ph14060519","volume":"14","author":"R Mansi","year":"2021","unstructured":"Mansi R, Fleischmann A, Macke HR (2021) Targeting gastrin-releasing peptide receptors in prostate cancer: current status and future directions. Pharmaceuticals 14(6):519. https:\/\/doi.org\/10.3390\/ph14060519","journal-title":"Pharmaceuticals"},{"key":"1137_CR40","doi-asserted-by":"crossref","unstructured":"Moazami-Ashtiani M, Rajabifar S, Zolghadri S, Yousefnia H (2025) [113mIn]In-AMBA: A novel diagnostic agent for SPECT imaging of GRPR-expressing tumors. Nucl Med Mol Imaging. (in press)","DOI":"10.1007\/s13139-025-00906-4"},{"key":"1137_CR43","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","volume":"58","author":"C Morgat","year":"2017","unstructured":"Morgat C, MacGrogan G, Brouste V, V\u00e9lasco V, Sevenet N, Bonnefoi H, Fernandez P, Debled M, Hindie E (2017) Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors. J Nucl Med 58:1401\u20131407. https:\/\/doi.org\/10.2967\/jnumed.116.188011","journal-title":"J Nucl Med"},{"key":"1137_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.14494\/jnrs.10.1_1","volume":"10","author":"M Mostafa","year":"2009","unstructured":"Mostafa M, El-Said AAES, MA H EA (2009) 99Mo\/99mTc-113Sn\/113mIn dual radioisotope generator based on 6-tungstocerate (IV) column matrix. J Nucl Radiochem Sci 10:11\u2013112. https:\/\/doi.org\/10.14494\/jnrs.10.1_1","journal-title":"J Nucl Radiochem Sci"},{"key":"1137_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.26850\/1678-4618eqj.v44.3.2019.p11-19","volume":"44","author":"FB Payolla","year":"2019","unstructured":"Payolla FB, Massabni AC, Orvig C (2019) Radiopharmaceuticals for diagnosis in nuclear medicine: A short review. Ecl\u00e9t Qu\u00ed 44:11\u201319. https:\/\/doi.org\/10.26850\/1678-4618eqj.v44.3.2019.p11-19","journal-title":"Ecl\u00e9t Qu\u00ed"},{"key":"1137_CR47","unstructured":"Pelowitz DB (2011) MCNPX user\u2019s manual. LA-CP-11-00438. Los Alamos National Laboratory"},{"issue":"1","key":"1137_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13246-024-01510-0","volume":"48","author":"S Ranjbar","year":"2025","unstructured":"Ranjbar S, Aghamiri SM, Rajabifar S, Zolghadri S, Yousefnia H (2025) [113mIn]In-RM2: A high potential agent for SPECT imaging of GRPR-expressing tumors. Phys Eng Sci Med 48(1):1\u201311. https:\/\/doi.org\/10.1007\/s13246-024-01510-0","journal-title":"Phys Eng Sci Med"},{"key":"1137_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.nucmedbio.2014.10.002","volume":"42","author":"TJ Reynolds","year":"2015","unstructured":"Reynolds TJ, Schehr R, Liu D, Xu J, Miao Y, Hoffman TJ, Rold TL, Lewis MR, Smith CJ (2015) Characterization and evaluation of DOTA-conjugated Bombesin\/RGD-antagonists for prostate cancer tumor imaging and therapy. Nucl Med Biol 42:99\u2013108. https:\/\/doi.org\/10.1016\/j.nucmedbio.2014.10.002","journal-title":"Nucl Med Biol"},{"key":"1137_CR50","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6498\/ad53d5","author":"DS Rond\u00f3n","year":"2024","unstructured":"Rond\u00f3n DS, Lombardo P, Abdelrahman M, Struelens L, Vanhavere F, Bergans N (2024) Object and person tracking systems to enable extremity dosimetry in nuclear medicine using computational methods. J Radiol Prot. https:\/\/doi.org\/10.1088\/1361-6498\/ad53d5","journal-title":"J Radiol Prot"},{"key":"1137_CR52","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00259-009-1216-8","volume":"37","author":"M Sandstr\u00f6m","year":"2010","unstructured":"Sandstr\u00f6m M, Garske U, Granberg D, Sundin A, Lundqvist H (2010) Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe 1-Tyr 3-octreotate. EJNMMI 37:212\u2013225. https:\/\/doi.org\/10.1007\/s00259-009-1216-8","journal-title":"EJNMMI"},{"issue":"1","key":"1137_CR53","first-page":"171","volume":"34","author":"JA Scott","year":"1993","unstructured":"Scott JA (1993) ICRU report 46: photon, electron, proton and neutron interaction data for body tissues. Int Comm Radiat Units Meas 34(1):171","journal-title":"Int Comm Radiat Units Meas"},{"key":"1137_CR54","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0020-708X(65)90182-1","volume":"16","author":"HS Stern","year":"1965","unstructured":"Stern HS, Zolle I, McAfee JG (1965) Preparation of technetium (Tc99m)-labeled serum albumin (human). Int J Appl Radiat Isot 16:283\u2013288. https:\/\/doi.org\/10.1016\/0020-708X(65)90182-1","journal-title":"Int J Appl Radiat Isot"},{"key":"1137_CR900","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06640-x","author":"C Stokke","year":"2024","unstructured":"Stokke C, Gnesin S, Tran-Gia J, Cicone F, Holm S, Cremonesi M, Blakkisrud J, Wendler T, Gillings N, Herrmann K, Mottaghy FM (2024) EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-024-06640-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1137_CR67","doi-asserted-by":"crossref","unstructured":"Stoykow Grillo C (2016) Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET. Theranostics 6:1641\u20131650","DOI":"10.7150\/thno.14958"},{"key":"1137_CR56","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","volume":"44","author":"A Sundl\u00f6v","year":"2017","unstructured":"Sundl\u00f6v A, Sj\u00f6green-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, Tennvall J (2017) Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. EJNMMI 44:1480\u20131489. https:\/\/doi.org\/10.1007\/s00259-017-3678-4","journal-title":"EJNMMI"},{"issue":"3","key":"1137_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"1137_CR58","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2967\/jnumed.121.262122","volume":"63","author":"G Tamborino","year":"2022","unstructured":"Tamborino G, Nonnekens J, De Saint-Hubert M, Struelens L, Feijtel D, de Jong M, Konijnenberg MW (2022) Dosimetric evaluation of the effect of receptor heterogeneity on the therapeutic efficacy of peptide receptor radionuclide therapy: correlation with DNA damage induction and in vivo survival. J Nucl Med 63:100\u2013107. https:\/\/doi.org\/10.2967\/jnumed.121.262122","journal-title":"J Nucl Med"},{"key":"1137_CR59","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.surg.2018.03.030","volume":"165","author":"JF Tierney","year":"2019","unstructured":"Tierney JF, Kosche C, Schadde E, Ali A, Virmani S, Pappas SG, Poirier J, Keutgen XM (2019) 68Gallium-DOTATATE positron emission tomography\u2013computed tomography (PET CT) changes management in a majority of patients with neuroendocrine tumors. J Surg 165:178\u2013185. https:\/\/doi.org\/10.1016\/j.surg.2018.03.030","journal-title":"J Surg"},{"key":"1137_CR60","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.2174\/0929867033456666","volume":"10","author":"V Tolmachev","year":"2003","unstructured":"Tolmachev V, Orlova A, Lundqvist H (2003) Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. Curr Med Chem 10:2447\u20132460. https:\/\/doi.org\/10.2174\/0929867033456666","journal-title":"Curr Med Chem"},{"key":"1137_CR61","doi-asserted-by":"publisher","first-page":"078203","DOI":"10.1088\/1674-1137\/39\/7\/078203","volume":"9","author":"W Wang","year":"2015","unstructured":"Wang W, Cheng MY, Long PC, Hu LQ (2015) Specific absorbed fractions of electrons and photons for Rad-HUMAN Phantom using Monte Carlo method. Chin Phys C 9:078203. https:\/\/doi.org\/10.1088\/1674-1137\/39\/7\/078203","journal-title":"Chin Phys C"},{"key":"1137_CR62","first-page":"161","volume":"5","author":"EM Wolin","year":"2012","unstructured":"Wolin EM (2012) The expanding role of somatostatin analogs in the management of neuroendocrine tumors. J Gastrointest Cancer Res 5:161","journal-title":"J Gastrointest Cancer Res"},{"issue":"7","key":"1137_CR63","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ejmp.2015.05.015","volume":"31","author":"H Yousefnia","year":"2015","unstructured":"Yousefnia H, Zolghadri S (2015) Estimated human absorbed dose of a new 153Sm bone seeking agent based on biodistribution data in mice: comparison with 153Sm-EDTMP. Phys Med 31(7):714\u2013719. https:\/\/doi.org\/10.1016\/j.ejmp.2015.05.015","journal-title":"Phys Med"},{"key":"1137_CR64","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/HP.0000000000001670","volume":"24","author":"KN Yu","year":"2023","unstructured":"Yu KN, Watabe H, Zivkovic M, Krstic D, Nikezic D, Kim KM, Yamaya T, Kawachi N, Tanaka H, Haque AK, Beni MS (2023) DynamicMC: an open-source GUI program coupled with MCNP for modeling relative dynamic movement of radioactive source and ORNL Phantom in a 3-dimensional radiation field. HPHY 24:301\u2013309. https:\/\/doi.org\/10.1097\/HP.0000000000001670","journal-title":"HPHY"},{"issue":"6","key":"1137_CR65","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s10967-024-09486-7","volume":"333","author":"S Zolghadri","year":"2024","unstructured":"Zolghadri S, Mohammadpour-Ghazi F, Yousefnia H (2024a) Preparation, quality control, and absorbed dose Estimation of 89Zr-DFO-Cetuximab for imaging of EGFR-expressing tumors. J Radioanal Nucl Chem 333(6):2639\u20132648. https:\/\/doi.org\/10.1007\/s10967-024-09486-7","journal-title":"J Radioanal Nucl Chem"},{"key":"1137_CR66","doi-asserted-by":"publisher","first-page":"111379","DOI":"10.1016\/j.apradiso.2024.111379","volume":"210","author":"S Zolghadri","year":"2024","unstructured":"Zolghadri S, Mohammadpour-Ghazi F, Yousefnia H (2024b) Preclinical studies and absorbed dose Estimation of [89Zr] Zr-DFO-Bevacizumab for PET imaging of VEGF-expressing tumors. Appl Radiat Isot 210:111379. https:\/\/doi.org\/10.1016\/j.apradiso.2024.111379","journal-title":"Appl Radiat Isot"}],"container-title":["Radiation and Environmental Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00411-025-01137-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00411-025-01137-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00411-025-01137-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:22:36Z","timestamp":1757316156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00411-025-01137-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1007\/s00411-025-01137-z","relation":{},"ISSN":["0301-634X","1432-2099"],"issn-type":[{"value":"0301-634X","type":"print"},{"value":"1432-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}